Full title: Study of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome (FCS)

Details: The purpose or AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all eligibility criteria will be randomized to receive 4 doses of ARO-APOC3 or matching placebo administered subcutaneously. Participants who complete the randomized period will continue in a 2-year open-label extension period where all participants will receive ARO-APOC3


Specialty: Endocrinology

Principal Investigator: Dr Damien Griffan

Study status: Follow up

Identifier: NCT05089084